Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CARv3-TEAM-E T-cells |
Synonyms | |
Therapy Description |
CARv3-TEAM-E T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting EGFRvIII and a T-cell engaging antibody molecule (TEAM) comprising a bispecific T-cell engager (BiTE) targeting wild-type EGFR, which potentially induce killing of tumor cells expressing EGFRvIII and wild-type EGFR (PMID: 38477966). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CARv3-TEAM-E T-cells | CD3 Antibody 99 EGFR Antibody 60 | CARv3-TEAM-E T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting EGFRvIII and a T-cell engaging antibody molecule (TEAM) comprising a bispecific T-cell engager (BiTE) targeting wild-type EGFR, which potentially induce killing of tumor cells expressing EGFRvIII and wild-type EGFR (PMID: 38477966). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05660369 | Phase I | CARv3-TEAM-E T-cells | CARv3-TEAM-E T Cells in Glioblastoma | Recruiting | USA | 0 |